LOS ALTOS, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that the University of Nebraska Medical Center (UNMC) is now enrolling patients with Locally Advanced Pancreatic Cancer (LAPC) in the Company’s ongoing pivotal Phase III TIGeR-PaC clinical trial.
University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial
RENOVORX INC
NASDAQ:RNXT (2/7/2025, 8:00:01 PM)
After market: 1.16 0 (0%)1.16
-0.3 (-20.55%)
RNXT Latest News and Analysis
17 hours ago - ChartmillWhat's going on in today's pre-market sessionDiscover the top movers in Friday's pre-market session and stay informed about market dynamics.
a day ago - ChartmillThese stocks are moving in today's after hours sessionLet's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
